Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
Michael C. Burger(Goethe University Frankfurt), Oliver Bähr(Antea Group (France))
Cited by 73
Related Papers
Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease
|JAMA Neurology|2025|7
Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis
|Neurology Neuroimmunology & Neuroinflammation|2025|0